1032350-13-2 | 8-(4-(1-Aminocyclobutyl)phenyl)-9-phenyl-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2h)-one dihydrochloride

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$12.00	$9.00
5mg	98%	in stock	$22.00	$15.00
10mg	98%	in stock	$38.00	$27.00
1g	98%	in stock	$612.00	$428.00

Description

• Catalog Number: AE11280
• Chemical Name: 8-(4-(1-Aminocyclobutyl)phenyl)-9-phenyl-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2h)-one dihydrochloride
• CAS Number: 1032350-13-2
• Molecular Formula: C25H23Cl2N5O
• Molecular Weight: 480.3890
• MDL Number: MFCD14584463
• SMILES: O=c1[nH]nc2n1ccc1c2cc(c(n1)c1ccc(cc1)C1(N)CCC1)c1ccccc1.Cl.Cl

Computed Properties

• Complexity: 760
• Covalently-Bonded Unit Count: 3
• Heavy Atom Count: 33
• Hydrogen Bond Acceptor Count: 4
• Hydrogen Bond Donor Count: 4
• Rotatable Bond Count: 3

Literature

• Plasticizer Di-(2-Ethylhexyl)Phthalate Induces Epithelial-to-Mesenchymal Transition and Renal Fibrosis In Vitro and In Vivo.

  Toxicological sciences : an official journal of the Society of Toxicology 20180701

• Gap junctional intercellular communication and endoplasmic reticulum stress regulate chronic cadmium exposure induced apoptosis in HK-2 cells.

  Toxicology letters 20180515

• Airborne nitro-PAHs induce Nrf2/ARE defense system against oxidative stress and promote inflammatory process by activating PI3K/Akt pathway in A549 cells.

  Toxicology in vitro : an international journal published in association with BIBRA 20171001

• Akt activation by Ca(2+)/calmodulin-dependent protein kinase kinase 2 (CaMKK2) in ovarian cancer cells.

  The Journal of biological chemistry 20170825

• Role of Exchange Protein Directly Activated by Cyclic AMP Isoform 1 in Energy Homeostasis: Regulation of Leptin Expression and Secretion in White Adipose Tissue.

  Molecular and cellular biology 20161001

• Taurocholate Induces Cyclooxygenase-2 Expression via the Sphingosine 1-phosphate Receptor 2 in a Human Cholangiocarcinoma Cell Line.

  The Journal of biological chemistry 20151225

• Utilization of human nuclear receptors as an early counter screen for off-target activity: a case study with a compendium of 615 known drugs.

  Toxicological sciences : an official journal of the Society of Toxicology 20150601

• Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines.

  Journal of cancer research and clinical oncology 20150401

• S6 inhibition contributes to isoflurane neurotoxicity in the developing brain.

  Toxicology letters 20150304

• The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer cells.

  Naunyn-Schmiedeberg's archives of pharmacology 20150101

• Elucidating mechanisms of toxicity using phenotypic data from primary human cell systems--a chemical biology approach for thrombosis-related side effects.

  International journal of molecular sciences 20150101

• Detection of key enzymes, free radical reaction products and activated signaling molecules as biomarkers of cell damage induced by benzo[a]pyrene in human keratinocytes.

  Toxicology in vitro : an international journal published in association with BIBRA 20140801

• PI3K signaling mediates diverse regulation of ATF4 expression for the survival of HK-2 cells exposed to cadmium.

  Archives of toxicology 20140201

• Preventing the calorie restriction-induced increase in insulin-stimulated Akt2 phosphorylation eliminates calorie restriction's effect on glucose uptake in skeletal muscle.

  Biochimica et biophysica acta 20121101

• A novel PKB/Akt inhibitor, MK-2206, effectively inhibits insulin-stimulated glucose metabolism and protein synthesis in isolated rat skeletal muscle.

  The Biochemical journal 20121001

• Phosphatidylinositol 3-kinase/Akt signaling pathway activates the WNK-OSR1/SPAK-NCC phosphorylation cascade in hyperinsulinemic db/db mice.

  Hypertension (Dallas, Tex. : 1979) 20121001

• Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model.

  Cancer research 20120901

• Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels.

  Oncotarget 20120801

• Combination of an allosteric Akt Inhibitor MK-2206 with etoposide or rapamycin enhances the antitumor growth effect in neuroblastoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120701

• Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120501

• The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells.

  The Journal of clinical endocrinology and metabolism 20120201

• MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis.

  Molecular cancer therapeutics 20120101

• Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestin.

  PloS one 20120101

• First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20111210

• IKBKE protein activates Akt independent of phosphatidylinositol 3-kinase/PDK1/mTORC2 and the pleckstrin homology domain to sustain malignant transformation.

  The Journal of biological chemistry 20111028

• The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma.

  Gynecologic oncology 20111001

• Next-generation Akt inhibitors provide greater specificity: effects on glucose metabolism in adipocytes.

  The Biochemical journal 20110415

• The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.

  The Journal of clinical endocrinology and metabolism 20110401

• eEF-2 kinase dictates cross-talk between autophagy and apoptosis induced by Akt Inhibition, thereby modulating cytotoxicity of novel Akt inhibitor MK-2206.

  Cancer research 20110401

• MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.

  Molecular cancer therapeutics 20100701

• Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo.

  PloS one 20100101